Wavegate Corporation Announces $26 Million Series A Funding Round Led by UCEA Capital Partners Ltd.

LAKE CHARLES, La., Dec. 10, 2024 /PRNewswire/ — Wavegate Corporation, a pioneering developer of neuromodulation technology for chronic pain management, has secured a lead investor in their $26 million Series A funding round led by UCEA Capital Partners Ltd., a London-based investment firm. This financing will accelerate the development of Wavegate’s proprietary Ellipse platform, featuring StimuLux technology, designed to provide breakthrough therapeutic solutions for chronic pain patients.

Wavegate Corporation has secured led investor UCEA Capital Partners Ltd. for its $26 million Series A funding round

Wavegate’s Ellipse spinal cord stimulator uses optical reflectometry to provide closed-loop adaptive modulation, uniquely adjusting stimulation in real-time based on spinal cord movement. This technology, which received FDA Breakthrough Device designation, offers significant potential to improve the lives of chronic pain sufferers by maintaining consistent pain relief across a range of patient activities using either paresthesia-based or paresthesia-free neuromodulation. Wavegate also recently achieved successful first-in-human data, further validating the clinical promise of its Ellipse platform.

“Securing this funding represents a pivotal moment for Wavegate as we continue to push the boundaries in neuromodulation technology,” said Dr. Erich Wolf, CEO of Wavegate Corporation. “UCEA’s investment validates the potential of our innovations and supports our vision of advancing effective, patient-centered pain management solutions.”

The investment by UCEA Capital Partners aligns with its strategic focus on supporting transformative healthcare technologies. “Wavegate’s approach to neuromodulation reflects exactly the type of high-impact, innovation-driven opportunity we seek to champion. We are thrilled to support their journey in addressing a critical area of unmet medical need,” noted Joao Teixeira, Chairman of UCEA Capital Partners Ltd.

The Series A funding will be instrumental in expanding Wavegate’s R&D efforts, clinical trials, and preparations for regulatory approvals, marking a significant step forward for the company as it progresses toward commercialization.

For more information on Wavegate Corporation, visit wavegate.us.

Media Contact:
Marla Miller, JD, LLM
Corporate Secretary
marla@wavegate.us
+1-337-419-1360

View original content to download multimedia:https://www.prnewswire.com/news-releases/wavegate-corporation-announces-26-million-series-a-funding-round-led-by-ucea-capital-partners-ltd-302328197.html

SOURCE Wavegate Corporation

Staff

Recent Posts

Plano Medical Waste Disposal Firm Addresses Alarming Increase in Needlestick Injuries With Comprehensive Guide

According to CDC estimates, about 385,000 incidents involving needlestick and sharps injuries are reported annually…

45 minutes ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or…

45 minutes ago

cbdMD, Inc. To Host Conference Call to Discuss September 30, 2024 Fourth Quarter and Fiscal Year 2024 Results

Charlotte, North Carolina--(Newsfile Corp. - December 12, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

3 hours ago

Silicon Carbide Battery Market to Reach USD 400.6 Million by 2030: Key Trends and Growth Drivers | Valuates Reports

Silicon Carbide Battery Market is Segmented by Type (Silicon Carbide Lithium Ion Battery, Silicon Carbide…

4 hours ago

Healthcare Executives Embrace Generative AI to Boost Patient Outcomes

Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 12, 2024 /PRNewswire/ -- USA…

4 hours ago

RIVANNA examines regional trends in anesthesiology workforce and diagnostic imaging growth

CHARLOTTESVILLE, Va., Dec. 12, 2024 /PRNewswire/ -- RIVANNA®, developers of world-first imaging-based medical solutions, has…

4 hours ago